CN111617047B - 一种含tbn或其盐或其水合物的药物组合物及其制备方法 - Google Patents

一种含tbn或其盐或其水合物的药物组合物及其制备方法 Download PDF

Info

Publication number
CN111617047B
CN111617047B CN201910143739.0A CN201910143739A CN111617047B CN 111617047 B CN111617047 B CN 111617047B CN 201910143739 A CN201910143739 A CN 201910143739A CN 111617047 B CN111617047 B CN 111617047B
Authority
CN
China
Prior art keywords
pharmaceutical composition
tbn
weight ratio
enteric
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910143739.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111617047A (zh
Inventor
刘伟
孙业伟
王玉强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Magpie Pharmaceuticals Co Ltd
Original Assignee
Guangzhou Magpie Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201910143739.0A priority Critical patent/CN111617047B/zh
Application filed by Guangzhou Magpie Pharmaceuticals Co Ltd filed Critical Guangzhou Magpie Pharmaceuticals Co Ltd
Priority to JP2021550131A priority patent/JP7404381B2/ja
Priority to US17/434,624 priority patent/US20220168299A1/en
Priority to EP19917480.6A priority patent/EP3932407B1/en
Priority to CA3131558A priority patent/CA3131558A1/en
Priority to AU2019431238A priority patent/AU2019431238B2/en
Priority to PCT/CN2019/098709 priority patent/WO2020173046A1/zh
Publication of CN111617047A publication Critical patent/CN111617047A/zh
Application granted granted Critical
Publication of CN111617047B publication Critical patent/CN111617047B/zh
Priority to IL285865A priority patent/IL285865A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201910143739.0A 2019-02-27 2019-02-27 一种含tbn或其盐或其水合物的药物组合物及其制备方法 Active CN111617047B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201910143739.0A CN111617047B (zh) 2019-02-27 2019-02-27 一种含tbn或其盐或其水合物的药物组合物及其制备方法
US17/434,624 US20220168299A1 (en) 2019-02-27 2019-07-31 Pharmaceutical composition comprising tbn, or salt or hydrate thereof, and preparation method thereof
EP19917480.6A EP3932407B1 (en) 2019-02-27 2019-07-31 Enteric coated tablet composition comprising tetramethylpyrazine nitrone
CA3131558A CA3131558A1 (en) 2019-02-27 2019-07-31 Pharmaceutical composition comprising tbn, or salt or hydrate thereof, and preparation method thereof
JP2021550131A JP7404381B2 (ja) 2019-02-27 2019-07-31 Ｔｂｎ、又はその塩もしくは水和物を含む薬物組成物及びその製造方法
AU2019431238A AU2019431238B2 (en) 2019-02-27 2019-07-31 Pharmaceutical composition containing tbn or salt or hydrate thereof and preparation method therefor
PCT/CN2019/098709 WO2020173046A1 (zh) 2019-02-27 2019-07-31 一种含tbn或其盐或其水合物的药物组合物及其制备方法
IL285865A IL285865A (en) 2019-02-27 2021-08-25 A pharmaceutical preparation containing tbn or a salt or hydrate thereof and a method for its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910143739.0A CN111617047B (zh) 2019-02-27 2019-02-27 一种含tbn或其盐或其水合物的药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
CN111617047A CN111617047A (zh) 2020-09-04
CN111617047B true CN111617047B (zh) 2021-06-22

Family

ID=72238958

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910143739.0A Active CN111617047B (zh) 2019-02-27 2019-02-27 一种含tbn或其盐或其水合物的药物组合物及其制备方法

Country Status (8)

Country Link
US (1) US20220168299A1 (enExample)
EP (1) EP3932407B1 (enExample)
JP (1) JP7404381B2 (enExample)
CN (1) CN111617047B (enExample)
AU (1) AU2019431238B2 (enExample)
CA (1) CA3131558A1 (enExample)
IL (1) IL285865A (enExample)
WO (1) WO2020173046A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109893511B (zh) * 2017-12-11 2022-07-12 湖北舒邦药业有限公司 一种地红霉素肠溶片肠溶包衣、其制备方法以及一种地红霉素肠溶片
CN111763178B (zh) * 2019-04-01 2023-02-03 广州喜鹊医药有限公司 硝酮嗪晶型、制备方法及应用
CN112516100A (zh) * 2020-12-31 2021-03-19 珠海润都制药股份有限公司 一种艾司奥美拉唑镁肠溶片及其制备方法
CN116650411A (zh) * 2022-02-25 2023-08-29 广州喜鹊医药有限公司 一种注射用硝酮嗪药物组合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101269049A (zh) * 2008-04-25 2008-09-24 广东药学院 磷酸川芎嗪微孔渗透泵控释片及其制备方法
CN101987081A (zh) * 2010-07-16 2011-03-23 钟术光 一种控释制剂
CN104922086A (zh) * 2015-06-21 2015-09-23 珠海润都制药股份有限公司 一种质子泵抑制剂肠溶片的制备方法
CN105963298A (zh) * 2016-05-06 2016-09-28 广州喜鹊医药有限公司 川芎嗪衍生物硝酮嗪在预防和治疗脑损伤疾病中的应用
CN107417631A (zh) * 2017-08-04 2017-12-01 广州喜鹊医药有限公司 一种氘代硝酮嗪化合物及其制备方法和在制药中的应用
WO2018177420A1 (zh) * 2017-03-31 2018-10-04 复旦大学 一种生物膜包载药物纳米晶体的制备方法及其用途
CN108815128A (zh) * 2018-05-25 2018-11-16 广东药科大学 一种磷酸-川芎嗪微孔渗透泵控释片的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1683345A (zh) * 2005-02-28 2005-10-19 杨喜鸿 川芎嗪的协同增效药用酸盐及其制备方法
CN101468970B (zh) * 2008-04-25 2011-05-11 暨南大学 一种硝酮类化合物及其制备方法和在制药中的应用
SI2659881T1 (en) * 2012-04-30 2018-03-30 Tillotts Pharma Ag Formulation of the delayed release medicinal product

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101269049A (zh) * 2008-04-25 2008-09-24 广东药学院 磷酸川芎嗪微孔渗透泵控释片及其制备方法
CN101987081A (zh) * 2010-07-16 2011-03-23 钟术光 一种控释制剂
CN104922086A (zh) * 2015-06-21 2015-09-23 珠海润都制药股份有限公司 一种质子泵抑制剂肠溶片的制备方法
CN105963298A (zh) * 2016-05-06 2016-09-28 广州喜鹊医药有限公司 川芎嗪衍生物硝酮嗪在预防和治疗脑损伤疾病中的应用
WO2018177420A1 (zh) * 2017-03-31 2018-10-04 复旦大学 一种生物膜包载药物纳米晶体的制备方法及其用途
CN107417631A (zh) * 2017-08-04 2017-12-01 广州喜鹊医药有限公司 一种氘代硝酮嗪化合物及其制备方法和在制药中的应用
CN108815128A (zh) * 2018-05-25 2018-11-16 广东药科大学 一种磷酸-川芎嗪微孔渗透泵控释片的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
川芎嗪硝酮衍生物在脑缺血模型大鼠脑中浓度;黎赛等;《中国临床药理学杂志》;20110630;第27卷(第6期);第446-453页 *
雷贝拉唑钠肠溶片处方筛选及评价;卢会芬等;《河北工业科技》;20160731;第33卷(第4期);第314-318页 *

Also Published As

Publication number Publication date
CA3131558A1 (en) 2020-09-03
US20220168299A1 (en) 2022-06-02
JP2022522005A (ja) 2022-04-13
CN111617047A (zh) 2020-09-04
JP7404381B2 (ja) 2023-12-25
IL285865A (en) 2021-10-31
WO2020173046A1 (zh) 2020-09-03
EP3932407A4 (en) 2022-06-29
AU2019431238A1 (en) 2021-10-28
AU2019431238B2 (en) 2023-09-28
EP3932407C0 (en) 2023-10-18
EP3932407B1 (en) 2023-10-18
EP3932407A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
AU2019268049B2 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
US20120039954A1 (en) Method of treating insomnia
CN111617047A (zh) 一种含tbn或其盐或其水合物的药物组合物及其制备方法
AT400521B (de) Verfahren zur herstellung einer festen oralen pharmazeutischen ketotifenzusammensetzung
US20150283091A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
JP2022522005A5 (enExample)
CN113645962A (zh) 含有富马酸二甲酯的肠溶片剂
EP2524688B1 (en) Composition for modified release comprising ranolazine
WO2017101858A1 (zh) 环苄普林之延释剂型
US20180071277A1 (en) Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
JP7084950B2 (ja) 非拍動性持続放出ベタヒスチン経口固形組成物
CN113521020B (zh) 一种含有水溶性酸的瑞德西韦固体剂型
WO2015055564A1 (de) Pharmazeutische darreichungsformen enthaltend natrium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olat
HK40009517A (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
HK40012188A (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
TWI600425B (zh) 環苄普林之延釋劑型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant